Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sawai: Sales Up 18% with Good Sales of New Products
December 1, 2008
- Medical Fee System Needs Reform to Deal with High-Cost Drugs: Dr Ishikawa
December 1, 2008
- Taiyo Yakuhin: Sales Up 11.9%
December 1, 2008
- GL on Proper Use of Psychotropics in the Elderly Expected by 2010
December 1, 2008
- Towa: Sales Up 12.8% due to Expansion of Sales to Pharmacies
December 1, 2008
- Standard Regimens for Colon Cancer Used in 56% of Cases
December 1, 2008
- Actavis ASKA Aims at Becoming Leading Generic House in Japan
December 1, 2008
- MEDICAL DEVICE NEWS IN BRIEF
December 1, 2008
- Greater Efforts Needed to Promote Use of Generics: Chuikyo
December 1, 2008
- CMIC Aims at Entry into Western Market to Become a Global CRO
December 1, 2008
- Irbesartan Fails to Improve Outcome of Heart Failure Patients with Preserved LVEF
December 1, 2008
- TOPICS／Number of MRs Decreases for First Time in 2007
December 1, 2008
- Subject Enrollment to a PIII Trial of AMG706 Stopped
December 1, 2008
- Combined Sales of TSE 1st Section-Listed 22 Pharmas Up 3.9%
December 1, 2008
- Standard Forms Adopted by Only 70% of Med Institutions Participating in Clinical Trials
December 1, 2008
- VITAL-NET, KSK to Merge to Create 5th Largest Drug Wholesaler
December 1, 2008
- R&D NEWS IN BRIEF
December 1, 2008
- Nippon Shinyaku: Sales Up 14.1% Due to Licensing of NS-304
November 24, 2008
- REGULATORY NEWS IN BRIEF
November 24, 2008
- Seikagaku: Good Domestic Sales Fail to Make Up for Decreases in Exports
November 24, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…